Does tumour dormancy offer a therapeutic target?

Nat Rev Cancer. 2010 Dec;10(12):871-7. doi: 10.1038/nrc2933. Epub 2010 Nov 4.


The increasing number of cancer survivors is cause for celebration, but this expanding population has highlighted the problem of tumour dormancy, which can lead to relapse. As we start to understand more about the biology of dormant cancer cells, we can begin to address how best to treat this form of disease. Preclinical models and initial clinical trials, as exemplified in patients with breast cancer, are paving the way to address how best to treat long-term cancer survivors to minimize the risk of cancer recurrence.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / mortality
  • Breast Neoplasms / pathology
  • Clinical Trials as Topic
  • Female
  • Humans
  • Neoplasm Metastasis
  • Neoplasm Recurrence, Local
  • Neoplastic Cells, Circulating
  • Receptor, ErbB-2 / antagonists & inhibitors
  • Survivors


  • ERBB2 protein, human
  • Receptor, ErbB-2